|
|
France Pharmaceuticals and Healthcare Report Q2 2008Published by: Business Monitor International Published: May. 16, 2008 - 78 Pages Table of Contents
AbstractThe French pharmaceutical sector is both large and dynamic with traditional strengths in production, and research & development (R&D). However, the government has decided that it can no longer support the conventionally generous state-spending on medicine, and has demanded that austerities be made in the sector. This appears to have had an impact in the last couple of years. But in 2007, growth crept up again by 3.5%, bringing the total market value to US$32.4bn. A part of the problem was that reimbursed drug spending for salaried workers had picked up and doctors were accused of not implementing prescribing restrictions correctly.Meanwhile, President Nicolas Sarkozy has continued with his promises of the past with a number of initiatives for the health sector. Besides stripping early retirees of their right to free healthcare, Sarkozyhas launched a five-year plan to tackle Alzheimer's disease, which will be funded by the recent imposition of a surcharge on medicine packs. The EUR1.6bn (US$2.4bn) plan will create a new research foundation to pool scientific resources and will set up a series of nursing homes. The surcharge programme, which was launched in January 2008, is raising revenues at the forecast level and is not resulting in falling demands for medicines. On the other hand, France's government healthcare advisory body, La Haute Autorité de Santé (HAS), has concluded that the country should reform the way chronic diseases are treated. BMI believes that the authorities will be keen to act on some of HAS’s suggestions to reduce the social security budget deficit. But any attempts perceived to involve a rationing of care will likely be met with fierce opposition, from both consumer groups and industry stakeholders. France has maintained its third position in BMI’s Business Environment Rankings for the Western European region. However, the French pharmaceutical association LEEM, has called for the government to provide greater support in R&D within the pharmaceutical sector. Specifically, the industry wants to see closer ties forged between public research and private enterprise. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||